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Abstract
Background: Real-time cardiovascular magnetic resonance (rtCMR) is considered attractive for guiding TAVI. Owing
to an unlimited scan plane orientation and an unsurpassed soft-tissue contrast with simultaneous device
visualization, rtCMR is presumed to allow safe device navigation and to offer optimal orientation for precise axial
positioning. We sought to evaluate the preclinical feasibility of rtCMR-guided transarterial aortic valve implatation
(TAVI) using the nitinol-based Medtronic CoreValve bioprosthesis.
Methods: rtCMR-guided transfemoral (n = 2) and transsubclavian (n = 6) TAVI was performed in 8 swine using the
original CoreValve prosthesis and a modified, CMR-compatible delivery catheter without ferromagnetic
components.
Results: rtCMR using TrueFISP sequences provided reliable imaging guidance during TAVI, which was successful in 6
swine. One transfemoral attempt failed due to unsuccessful aortic arch passage and one pericardial tamponade with
subsequent death occurred as a result of ventricular perforation by the device tip due to an operating error, this
complication being detected without delay by rtCMR. rtCMR allowed for a detailed, simultaneous visualization of the
delivery system with the mounted stent-valve and the surrounding anatomy, resulting in improved visualization
during navigation through the vasculature, passage of the aortic valve, and during placement and deployment of the
stent-valve. Post-interventional success could be confirmed using ECG-triggered time-resolved cine-TrueFISP and
flow-sensitive phase-contrast sequences. Intended valve position was confirmed by ex-vivo histology.
Conclusions: Our study shows that rtCMR-guided TAVI using the commercial CoreValve prosthesis in conjunction
with a modified delivery system is feasible in swine, allowing improved procedural guidance including immediate
detection of complications and direct functional assessment with reduction of radiation and omission of contrast
media.
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Background
Transarterial aortic valve implantation (TAVI) has
become a viable minimally-invasive treatment option for
high-risk and non-surgical patients with severe sympto-
matic aortic stenosis [1]. Its remarkable clinical success
has led to a revolutionary dissemination of this catheter-
based treatment, which is currently performed in an
ever-increasing number of patients with either the bal-
loon-expandable Edwards Sapien (Edwards Lifesciences
Inc., Irvine, CA, USA)[2] or the self-expandable Medtro-
nic CoreValve (Medtronic, Inc., Minneapolis, MN, USA)
[3] bioprosthesis, especially since Conformité Europé-
enne approval. However, despite various advancements
over the last years, TAVI remains a technically demand-
ing interventional procedure including various challen-
ging steps and a variety of potential procedural
complications. A major procedural challenge during
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native aortic valve annulus, correct placement of the
stent-valve being of paramount importance for proce-
dural success and for patient outcome [4]. Ventricular
embolization, coronary artery obstruction, or valve dislo-
cation into the ascending aorta may lead to acute,
potentially life-threatening complications, and even less
severe malpositioning is associated with an increased
rate of complications such as the occurrence of signifi-
cant paravalvular regurgitation, which has been shown
to negatively affect both immediate [5] and longer-term
[3] outcome, or the need for novel pacemaker implanta-
tion [6] when the prosthesis is implanted too low.
Both procedural safety and valve positioning accuracy
are influenced by the imaging modality used for proce-
dural guidance. Currently, TAVI is guided by X-ray
fluoroscopy and angiography. X-ray fluoroscopy and
angiography, however, entail several shortcomings such
as (a) radiation exposure, (b) limited 2D projection-like
visualization with little soft-tissue contrast, which
impairs immediate recognition of procedural complica-
tions (e.g. pericardial tamponade), and (c) the need for
repeated injections of nephrotoxic contrast media to
opacify the large-caliber aorta in order to determine the
aortic annulus and the location of the coronary ostia
during valve positioning and implantation. Although
transoesophageal echocardiography including real-time
3D imaging may be used as a helpful adjunct imaging
modality during TAVI [7], this technique has not elimi-
nated the need for fluoroscopy and angiography and
may itself cause complications. Moreover, it requires
general anaesthesia instead of conscious sedation, which
is desirable and increasingly used for TAVI. To over-
come the limitations of conventional X-ray-fluoroscopy
and angiography, guidance systems are currently under
development that aim to facilitate the TAVI procedure
for the X-ray operator [8-10]. C-arm computed tomo-
graphy with automatic aorta segmentation and valve
landmark detection represents such a technique that
seeks to simplify implantation of the stent-valve by guid-
ing valve positioning and deployment utilizing 3D over-
lay with the fluoroscopic images [9,10]. Nevertheless,
such techniques still require fluoroscopy and angiogra-
phy and do not offer a simultaneous, real-time acquisi-
tion of cardiovascular anatomy and the TAVI devices.
Cardiovascular magnetic resonance (CMR), on the
other hand, offers real-time image acquisition with
unrestricted scan plane orientation and unsurpassed
soft-tissue contrast with simultaneous visualization of
the interventional device and appears, therefore, poten-
tially advantageous over X-ray fluoroscopy and angiogra-
phy during device navigation through the vasculature,
during passage of the native aortic valve, and during
valve implantation. It permits on-line monitoring of
cardiac function, immediate detection of vascular and
cardiac damage, and real-time orientation for axial posi-
tioning and deployment of the prosthesis. Since all this
may even be achieved without the need for nephrotoxic
contrast media, not even gadolinium, real-time CMR
(rtCMR) may also help to reduce the risk of postproce-
dural acute kidney injury, which has been shown to
quadruple the risk of postoperative mortality in the
elderly TAVI patient population who often present with
pre-existing chronic kidney disease [11]. In addition to
improved procedural guidance, CMR is useful for pre-
interventional diagnostic evaluation of the aortic valve
[12] and the vascular aortic anatomy for interventional
planning, as well as for immediate evaluation of the
result [13-15]. Thus, CMR may be envisioned as a single
imaging modality for TAVI covering diagnostic, pre-
interventional evaluation, procedural guidance, and
post-interventional ascertainment of treatment success.
TAVI also appears particular l ya t t r a c t i v ef o raC M R -
guided approach, since device delivery is performed
through large-diameter vessels (femoral or subclavian
artery) and the delivery devices come with a rather large
instrument caliber. Hence, TAVI is amenable to passive
catheter tracking and may be performed without the
need for additional, sophisticated device modifications
as needed for active visualization approaches [16], mak-
ing it easier to ensure CMR compatibility and safety.
Our group has recently demonstrated in vitro that the
commercially available, nitinol-based CoreValve bio-
prosthesis is suited for rtCMR-guided placement when
using a modified and CMR-compatible delivery system,
while the stainless steel-based Edwards Sapien stent-
valve is not [17]. Based on these observations we pur-
sued the idea of rtCMR-guided TAVI in vivo and sought
to evaluate the preclinical feasibility of rtCMR-guided
CoreValve implantation in swine as briefly reported in a
recent research correspondence [18].
Methods
Animal preparation
In-vivo experiments were performed on 8 female
domestic pigs weighing 70.5 to 86.5 kilograms. The
experiments were conducted in approved animal facil-
ities by an experienced and qualified (Federation of Eur-
opean Laboratory Animal Science Association
certification) team including one attending veterinarian.
All procedures were performed in accordance with cur-
rent guidelines and legal requirements and were author-
ized by the regional governmental animal care and use
committee (TSG G 1078/09; Duesseldorf, Germany).
Anaesthesia was performed according to a well-proven
protocol for CMR interventions in pigs [19]. In brief,
the animals were sedated initially by intramuscular
injection of ketamine (30 mg/kg), azaperone (2 mg/kg)
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continuous infusion of propofol (2.29 mg/kg/h), midazo-
lam (1.14 mg/kg/h) and fentanyl (0.009 mg/kg/h) for
full anaesthesia. The pigs were intubated with an endo-
tracheal tube and ventilated with 30% oxygen using a
respirator (Oxylog 1000, Dräger Medical, Lübeck, Ger-
many) with a ventilation rate of 10 to 12 breaths per
minute. During the procedure, the animals were hepari-
nized after sheath insertion and monitored with electro-
cardiogram (ECG) and oxygen saturation. After the
experiment, the fully anaesthetized animals were eutha-
nized by intravenous bolus injection of pentobarbital (80
mg/kg), as mandated by the experimental protocol and
animal use guidelines.
TAVI device and CMR-compatible guidewire
A recent, comprehensive in-vitro study by our group has
demonstrated that the commercially available nitinol-
based, self-expandable CoreValve bioprosthesis is poten-
tially suited for rtCMR-guided placement using passive
device visualization and real-time fast imaging with
steady-state precession (TrueFISP) sequences [17].
While the commercial CoreValve prosthesis - providing
artifact-free and detailed CMR-visualization and being
already approved for safe CMR application in a static
magnetic field of up to 3 Tesla - needed no modifica-
tions prior CMR application, its dedicated delivery sys-
tem required effective modifications towards CMR
compatibility and safety, which were performed with the
help of Evasc Medical Systems (Evasc Medical Systems,
Vancouver, BC, Canada). In summary, the modified
delivery system was constructed with a polytetrafluor-
oethylene outer shaft and a nylon stabilizer tube without
the use of any reinforcing ferromagnetic or electrically
conducting wire braids or marker bands, which could
potentially be object to radiofrequency heating in the
CMR environment, but with preservation of rigidity and
flexibility that resulted in a slight but practically negligi-
ble increase in the crossing profile from 18 to 20 French
- when compared to the original CoreValve delivery
catheter (Figure 1). For implantation, a deployment han-
dle slides towards a stabilizer handle that is kept in a
fixed position. This mechanism, which is common to
other self-expandable devices (e.g. aortic stent grafts),
Figure 1 The modified delivery device. Photograph and schematic drawing of the modified, CMR-compatible delivery device for the
CoreValve prosthesis with labeling of the relevant parts (A, reprinted from [17]). Photograph of both the expanded CoreValve prosthesis and the
crimped stent-valve loaded in the polytetrafluoroethylene delivery catheter which offers stepwise valve deployment (B)
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nol stent-frame just like the original delivery system.
Though not additionally endowed with the hinge and eye-
let principle of the original device, the modified delivery
device mechanically constrains the unsheathed part of the
prosthesis safely until the first two thirds of the stent - the
inflow part that anchors the stent-valve in the native annu-
lus and the waisted mid-portion that guarantees unim-
peded coronary artery perfusion - are expanded. This
allows the operator to prevent stent displacement towards
the left ventricle, which is commonly encountered during
CoreValve implantation, by constantly pulling back the
delivery system until the inflow part of the stent-valve is
correctly anchored at the intended landing zone without
accidentally releasing the prosthesis - similar to the origi-
nal device. In-vitro, the modified, custom-built delivery-
catheter provided excellent, artifact-free real-time visuali-
zation of catheter movement and valve deployment using
fast TrueFISP sequences [17].
As for guidewires, which are currently a requirement
for the TAVI procedure in vivo, we evaluated an CMR-
compatible 0.035 inch polyetheretherketone-based pro-
totype guidewire (Biotronik Vascular Intervention, Bue-
lach, Switzerland) that has previously been used for
(supra)aortic and iliac stenting as well as cava filter pla-
cement under rtCMRI guidance [20].
Experimental protocol
In the sterile setting of a hybrid operative theatre with
full anaesthesiological, surgical and angiographic equip-
ment [21], a 22 F introducer sheath was surgically
inserted into the common femoral artery for the transfe-
moral approach and into the subclavian artery for the
transsubclavian approach. Angiography was performed
to depict vascular and aortic valve anatomy, and deliv-
ery-device introduction and aortic valve passage were
tested under fluoroscopic guidance. The obtained
movies and still frames were digitally stored for later
comparison of image quality and depicted information
with CMR, but were not available during the subsequent
CMR guided procedure. The delivery device was
removed and the animals were transferred to the nearby
CMR scanner room. After pre-interventional evaluation
using standard CMR sequences, rtCMR guided TAVI
was performed using TrueFISP sequences with subse-
quent CMR validation of procedural success. The pigs
were then euthanized and intended valve positioning
verified by ex-vivo histology.
CMR scanner and sequences
Scanning was performed on a 1.5-Tesla whole-body
CMR scanner (Magnetom Avanto, Siemens Healthcare
Sector, Erlangen, Germany) equipped with a gradient
system capable of a maximum amplitude of 40 mT/m
and a slew rate of 200 T/m s
-1. The animals were placed
head first in a supine position inside the scanner on a
multichannel spine phased-array radiofrequency (RF)
coil with three 3-channel clusters of RF coil elements
activated for signal reception (Tim technology, Siemens
Healthcare Sector, Erlangen, Germany). Two 6-channel
BodyFlex phased-array RF coils were placed anterior on
the pig for signal reception. This setting has been pre-
v i o u s l yu s e db yo u rg r o u pt oe v a l u a t et h o r a c i ca o r t i c
stent-grafts for rtCMR-guided placement in vivo [22].
Pre-interventional CMR evaluation
For pre-interventional preparation, vascular and cardiac
anatomy was assessed using standard CMR sequences.
Three-point localizer sequences were used to obtain
optimal scan planes to depict the relevant anatomic car-
diac and vascular landmarks. These scan planes were
used for pre-interventional evaluation with steady-state
free precession imaging with ECG gating and time-
resolved retrospective image reconstruction (cine-True-
FISP retro) (imaging parameters: repetition time (TR) 40
ms, echo time (TE) 1,1 ms, flip angle 62°, field-of-view
(FOV) 380 × 330 mm
2, matrix 192 × 168, slice thickness
6 mm, bandwidth 930 Hz/pixel, image acquisition time
(TA) 15 s for a single slice acquired over 20 phases of
the cardiac R-R interval) and provided the basis for
rtCMR guidance during subsequent implantation (see
below). Flow-sensitive phase-contrast (PC) sequences
were used to measure time-resolved aortic blood flow.
ECG-triggered through-plane PC sequences and in-
plane PC sequences in parasagittal orientation were
used (imaging parameters: TR 62 ms, TE 3.5 ms, flip
angle 30°, FOV 320 × 220 mm
2, matrix 192 × 132,
bandwidth 555 Hz/pixel, TA 1:52 minutes) with the
velocity-encoded value (VENC) set to 100 cm/s on the
basis of priorly acquired VENC scout sequences with
VENCs ranging from 60 to 120 cm/s.
Real-time CMR for interventional guidance
Interventional imaging guidance of the TAVI procedure
was performed under rtCMR fluoroscopy. rtCMR
fluoroscopy was based on a commercially available inter-
active real-time projection reconstruction TrueFISP
sequence with radial k-space filling during free breathing
and without cardiac triggering that was modified to
achieve a frame rate of 7 frames per second (imaging
parameters: TR 3.0 ms, TE 1.5 ms, flip angle 70°, FOV
360 × 360 mm
2, matrix 192 × 192, bandwidth 1530 Hz/
pixel, slice thickness 6 mm). Using sliding window
reconstruction, forty-nine echoes were acquired for each
new reconstructed image, resulting in real-time images
with a frame rate of seven reconstructed frames per sec-
ond. Images were displayed without detectable image
reconstruction delay (< 200 ms). The images were
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ventional in-room console (Siemens Healthcare Sector,
Erlangen, Germany) to provide real-time visualization
for the operator (PK). Image slice position, orientation
and contrast parameters could be changed and adapted
interactively from inside the scanner room while the
sequence was running. For implantation, image position
was adjusted in parasagittal orientations as needed to
display the abdominal and thoracic aorta, the aortic arch
and the ascending aorta including aortic annulus, left
ventricular outflow tract (LVOT), left ventricle and
mitral valve, respectively.
Post-interventional validation
Following TAVI, real-time TrueFISP, cine-TrueFISP
retro and flow-sensitive PC sequences were used to vali-
date procedural success. cine-TrueFISP imaging was used
for anatomic confirmation of adequate valve placement
across the native aortic annulus and in relation to the
LVOT and the mitral valve. Moreover, TrueFISP images
were used to evaluate for periinterventional complica-
tions such as impairment of ventricular function, mitral
valve function and pericardial effusion. PC sequences
were repeated after TAVI to confirm good systolic blood
flow without diastolic regurgitation indicating valvular or
paravalvular leakage. While ECG-triggered, velocity-
encoded, in-plane phase-contrast sequences in parasagit-
tal orientation were used for visual, qualitative assess-
ment of transvalvular blood flow after CoreValve
implantation, through-plane phase-contrast sequences
were used for quantitative assessment. Thereto, PC flow-
curves integrated over time were obtained approximately
1 cm below and 1 cm above the prosthesis. This “safety
margin” was chosen in order to avoid susceptibility arti-
facts and field distortion artifacts that might impact cor-
rect assessment of velocity and flow in terms of over- or
underestimation. After completion of the post-interven-
tional validation and on-table-euthanzation, macroscopic
examinations of the explanted hearts were performed for
validation of CMR-findings.
Statistical analysis
Continuous variables are presented as means and stan-
dard deviations. Agreement of measurements based on
cine-TrueFISP retro images with measurements on prior
angiographic images and with autopsy results was deter-
mined by comparing differences to zero by t-test. A p
value less than 0.05 was considered statistical significant.
Results
Pre-interventional evaluation
Three-point localizer sequences allowed for rapid detec-
tion (11 ± 3 minutes) and planning of all scan planes
required for pre-interventional evaluation and for
subsequent interventional guidance. Subsequent cine-
TrueFISP retro sequences provided high-resolution,
time-resolved images for a detailed assessment of the
relevant cardiac and vascular structures with an acquisi-
tion time of 15 seconds (Figure 2). Measurements based
on cine-TrueFISP retro images revealed an aortic annu-
lus size of 17 ± 3 mm as measured in a sagittal, long-
axis LVOT view which has the same orientation as the
midoesophageal long-axis view on transoesophageal
echocardiography that is routinely used for sizing mea-
surements in clinical practice, an aortic arch diameter of
21 ± 4 mm and a distance of 9 ± 3 and 10 ± 2 mm
from the aortic annulus to the left and right coronary
ostium. Annulus measurements were in good accor-
dance with measurements on prior angiographic images
(mean error: 0.4 ± 0.3 mm, p = ns) and did not differ
from autopsy results (mean error: 0.5 ± 0.2 mm, p = ns)
demonstrating the accuracy of CMR. Access vessel size
was 6.9 ± 1.2 mm and there were neither calcifications
nor tortuosity impeding insertion of the 22 French
access sheath and propagation of the delivery device.
Based on these measurements, the small CoreValve
prosthesis (26 mm) was chosen for implantation in all
pigs. Since the stent-frame - which is designed to be
placed into the LVOT and across the aortic annulus
with the sutured valve in supravalvular position - is
designed for use in humans with annulus sizes between
20 and 23 mm, the prosthesis was, in effect, oversized
for the animals. In addition, the ascending aorta of the
pig was less elongated when compared to human anat-
omy and, thus, somewhat short for the 55 mm long
prosthesis which is anchored there by its wide upper
portion. These anatomical limitations of the pig model
were accounted for during subsequent valve implanta-
tion. As a consequence, we intentionally aimed at var-
ious implantation depths of the proximal stent-frame
within a target area between 4 and 20 mm below the
aortic annulus, a range covering the usual implantation
depth in humans [23]. Using the 8 mm diamond cell
configuration for crude orientation, analog to human
implantations, we started with “deep” implantations
within this target area and gradually aimed at “higher”
implantations over the course of our experiments to
evaluate which depth would be optimal with respect to
pig anatomy. Nevertheless, prerequisites for successful
implantation were a functional placement of the Core-
Valve prosthesis across the aortic annulus without ven-
tricular embolization, coronary artery obstruction or
dislocation in the ascending aorta and maintenance of
structural and functional integrity of the mitral valve.
Real-time CMR for interventional guidance
rtCMR allowed for simultaneous visualization of the
vasculature and the delivery system with the mounted
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tional guidance. Mild susceptibility artifacts confined to
the loaded stent-valve enabled adequate determination
of the position of stent-valve and delivery system in
relation to the surrounding anatomy without undue
image distortion. This allowed for well-visualized propa-
gation of the device through the vasculature superior to
fluoroscopy which lacks the detailed soft-tissue contrast
provided by CMR (Figure 3).
In the first transfemoral animal, however, aortic arch
passage remained unsuccessful. The delivery system
with the mounted stent-valve could easily be advanced
from the femoral artery access site through the thoraco-
abdominal aorta, but the CMR-compatible guidewire -
though well steerable and pushable - did not provide
enough stiffness to allow passage of the rather steep aor-
tic arch resulting in inability to correctly implant the
valve which was finally deliberately deployed in the
Figure 2 High-resolution CMR images (cine-TrueFISP retro) of aortic valve and cardiac anatomy in parasagittal (A, B) and axial
orientations (C, D) allowing precise, pre-interventional evaluation for rtCMR-guided TAVI. The aortic annulus can be measured in the two
orthogonal long-axis views (A, B), while aortic valve area can be clearly determined in the short-axis view during systole (D)
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with perfect visualization (Figure 4A). Given the guide-
wire’s insufficient stiffness for TAVI, we continued our
experiments without the guidewire and focused on the
subclavian approach, since it offers a more straight
access route towards the aortic valve. Nevertheless, aor-
tic arch passage was successful in the second transfe-
moral animal (Figure 4B).
In the following animals, rtCMR provided good visua-
lization for navigation of them o u n t e ds t e n t - v a l v ef r o m
the subclavian access site towards the aortic valve. In
three animals, the device was initially advanced into the
descending aorta. Due to the detailed soft-tissue con-
trast provided by CMR, this was immediately detected
in real-time with good advantage over fluoroscopy and
corrected. After successful steering into the ascending
aorta, the aortic valve was carefully passed and the deliv-
ery devices were advanced until the device tips were
located in the left ventricular apex. This maneuver was
successful in all but one pig, in which the delivery
device was inadvertently pushed with too much force
too far into the left ventricle. This operating error
caused ventricular perforation by the device tip with
subsequent pericardial tamponade, which was detected
without delay by rtCMR. The animal was euthanized
when hemodynamic instability developed. In the other
five pigs, rtCMR verified correct position of the delivery
device tip in the left ventricular apex without signs of
tissue damage. The susceptibility artifacts of the loaded
stent-valve in combination with the simultaneously visi-
ble aortic annulus and mitral valve allowed for an ade-
quate initial positioning of the prosthesis prior to
release. Subsequently, the stent-valve was released step-
wise with continuous adjustments of the position and
successfully deployed under precise rtCMR visualization
at the intended landing zone without dislocation (Figure
5). Thereto, a constant pull was exerted on the catheter
system during deployment to compensate the typical
Figure 3 Comparison of rtCMR (A) and fluoroscopic guidance (B) during aortic valve passage. rtCMR provides real-time anatomic
orientation with excellent soft-tissue contrast (A, left image). Fluoroscopy lacks this detailed soft-tissue contrast and requires (repeated) injection
of contrast media to obtain a reliable orientation of the surrounding anatomy (B, left image). Moreover, rtCMR offers clear determination of the
position of the delivery device and, especially, the delivery device tip similar to fluoroscopy (A and B, middle and right images). Note the
bending of the delivery device tip in the middle image. With rtCMR it can be clearly determined that the delivery device is stuck in the left
coronary cusp of the aortic valve and needs to be retracted and advanced again for safe valve passage. Once the valve is passed, rtCMR allows
for precise advancement of the delivery catheter until the device tip is located in the left ventricular apex (A, right image)
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due to the tendency of the self-expandable stent-frame
to occupy the largest space available. Lacking the excel-
lent soft-tissue contrast of CMR, fluoroscopic guidance,
for comparison, did not allow a real-time anatomic
orientation during aortic valve passage and during posi-
tioning of the stent-valve, and required repeated con-
trast injections for adequate orientation (Figure 3).
After valve deployment, withdrawal of the delivery sys-
tem was also adequately visualized under rtCMR. No
other complications occurred. rtCMR acquisition time
for instrument navigation, positioning and deployment
of the prosthesis was 4 ± 2 minutes.
Post-interventional validation
Post-interventional CMR validation demonstrated a
functional CoreValve bioprosthesis deployed across the
aortic annulus within the intended target area between
4 and 20 mm in the LVOT and with maintenance of
structural and functional integrity of the mitral valve
and patency of the coronary ostia in all animals, as later
additionally confirmed by macroscopic examination of
the explanted hearts (Figure 6). Due to the relatively
short ascending aorta in the pig model, a position
approximately 10-15 mm in the LVOT provided the
best anatomical results (Figure 6). A higher implantation
- which may be considered optimal in humans - resulted
in a position of the upper portion of the stent frame
close to the insertion of the head vessels, while a deeper
implantation in the left ventricular outflow tract lead to
a close vicinity to the mitral valve, potentially impairing
function, though this was not observed in our study
(Figure 7). Flow-sensitive, ECG-triggered PC sequences
confirmed good systolic transvalvular blood flow without
diastolic regurgitation excluding valvular or paravalvular
leakage in all implanted valves (Figure 8) as expected in
view of the fact that an oversized prosthesis was used.
The total procedure time was 61 ± 13 minutes.
Discussion
The present study demonstrates the preclinical feasibil-
i t yo fe n t i r e l yC M R - g u i d e dT A V Ii nas w i n em o d e l .
Figure 4 Transfemoral TAVI under CMR guidance using real-time TrueFISP sequences. Safe advancement of the delivery system with the
mounted stent-valve up to the aortic arch which could not be passed in the first animal, resulting in controlled release of the prosthesis in the
thoracic aorta distal to the left subclavian artery (A). Stepwise deployment of the CoreValve prosthesis across the native aortic annulus in the
second transfemoral animal (B). Note the distinct susceptibility artifacts of the delivery system and the stent-valve, allowing precise determination
of the position of the delivery device tip (bracket) and the mounted stent-valve (arrow)
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eValve prosthesis without alterations and a modified,
CMR-compatible delivery device. As a single imaging
modality, CMR provided (a) comprehensive diagnostic
evaluation of the relevant cardiac and vascular anatomy
for adequate interventional planning, (b) reliable proce-
dural guidance in real-time, (c) immediate evaluation of
procedure-related complications, and (d) post-
interventional validation of treatment success. The con-
cept of rtCMR-guided TAVI was first described by
Kuehne et al. in 2004. This archetype study in the pre-
clinical, pioneering days of TAVI demonstrated the gen-
eral technical feasibility and potential value of rtCMR
guidance in acute animal experiments [24]. The authors
implanted entirely custom-built self-expanding, nitinol-
based stent-valves into the native aortic valves of seven
Figure 5 Transsubclavian TAVI under CMR guidance using real-time TrueFISP sequences. The CoreValve prosthesis was deployed stepwise
across the aortic annulus under rtCMR monitoring using the commercially available interactive real-time projection reconstruction TrueFISP
sequence with radial k-space filling during free breathing and without cardiac triggering. The sequence provides excellent instrument-to-
background contrast and a high frame rate of 7 fps allowing for accurate positioning and for detailed monitoring of the valve deployment
process.
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were loaded into a 10 French delivery catheter with two
ferromagnetic markers and successfully implanted via the
carotid and iliac artery. Subsequently, McVeigh et al.
described the rtCMR-guided implantation of custom-
built balloon-expandable stent-valves delivered by the
surgical, transapical approach in Yorkshire swine [25].
They used conventional stentless aortic bioprostheses
sutured into a commercial platinum-iridium stent and
mounted onto a commercial balloon catheter. In their
initial study, rtCMR-guided implantation with passive
device visualization was technically successful in 6 out of
8 animals with 2 procedural deaths after valve deploy-
ment due to coronary artery obstruction and 2 additional
procedural deaths during device manipulation. The same
group further pursued the transapical approach focusing
on chronic animal studies using their balloon-expandable
valve [26] and, very recently, a custom-built self-expand-
able stent-valve for comparison [27]. Interestingly, the
authors demonstrated shorter procedure times and easier
manipulation with the self-expandable device, resulting
in fewer procedural complications.
These custom-built, CMR-compatible devices provide
excellent visualization for rtCMR guidance. Our study
benefits from the use of the commercial, Conformité
Européenne certified CoreValve bioprosthesis, which is
already well-tested in the clinical arena with thousands
of human implantations world-wide. The original Core-
Valve bioprosthesis in combination with a modified,
CMR-compatible delivery device was chosen on the
basis of a previous comprehensive in vitro evaluation of
both currently commercially available stent-valves and
their delivery catheters, which was recently performed
by our group [17].
As shown by the present study, passive device visuali-
zation using real-time TrueFISP imaging with radial k-
space filling provided excellent real-time visualization of
the delivery system with the mounted CoreValve pros-
thesis and the surrounding anatomy during (a) naviga-
tion through the vasculature towards the aortic valve,
(b) aortic valve passage, (c) initial positioning, (d) device
deployment, and (e) catheter withdrawal. Such steady-
state sequences, when used with high excitation flip
angles, provide a high blood signal even without admin-
istration of a contrast agent and thus provide good
instrument-to-background contrast in the CMR image
[16]. The temporal resolution of seven reconstructed
images per second, displayed without detectable image
reconstruction delay on an in-room monitor, proved
sufficient for direct and precise control of catheter
movement. Moreover, rtCMR provided real-time moni-
toring of cardiac function and rapid detection of proce-
dural complications.
I n6o ft h e8a n i m a l s ,a2 6m mC o r e V a l v ep r o s t h e s i s
was successfully placed across the native aortic annulus
with implantation depths between 4 and 20 mm into
the LVOT without ventricular embolization or disloca-
tion into the ascending aorta, without coronary artery
obstruction, and without structural or functional impair-
ment of the mitral valve as confirmed by ex-vivo histol-
ogy. Two implant failures occurred in our series. The
first was a result of unsuccessful aortic arch passage and
resulted in a controlled deployment of the stent-valve in
the thoracic aorta distal to the left subclavian artery.
Though considered an implant failure in this case, a
controlled, safe deployment of the CoreValve prosthesis
in the thoracic aorta without accidental vessel obstruc-
tion is sometimes required in clinical application when
Figure 6 Macroscopic examination of an explanted heart after rtCMR-guided TAVI. The CoreValve prosthesis is correctly implanted across
the aortic annulus with an implantation depth of approximately 12 mm into the LVOT (A). The waisted middle portion of the stent-valve is
placed above the coronary ostia, thereby maintaining coronary artery perfusion as indicated by the probes (B, C)
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aorta during deployment and cannot be retrieved, as
observed in approximately 10% of cases [4]. The second
implant failure occurred due to perforation of the left
v e n t r i c u l a ra p e xb yt h ed e l i v e r yd e v i c et i pa sar e s u l to f
an avoidable operating error, which was not related to
periprocedural imaging guidance. However, this compli-
cation, which is observed in ~1% of cases [3], was
detected by rtCMR without time delay and without the
need for an additional imaging modality such as echo-
cardiography. Both cases indicate that rtCMR might
improve both precision and safety of the TAVI
procedure.
In addition to improved procedural guidance, CMR pro-
vided a reliable pre-interventional diagnostic evaluation
before as well as an adequate post-interventional
Figure 7 Macroscopic images of a very high implantation across the aortic annulus with minimal implantation depth (A) and a deep
implantation with an implantation depth of approximately 20 mm into the LVOT (B). While the high implantation resulted in a position
of the upper part of the CoreValve stent-frame close to the supraaortic arteries due to the short ascending aorta of the pigs (A), the deep
implantation demonstrated a close vicinity of the proximal stent-frame to the mitral valve (B)
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demonstrate that high-resolution TrueFISP retro
sequences enable detailed visualization of all anatomic
landmarks required for TAVI and allowed precise struc-
tural evaluation of the procedural result with good accor-
dance with autopsy findings. It should be noted here, that
CMR as a 3D imaging modality can also provide a com-
prehensive assessment of the elliptical shaped aortic annu-
lus in different scan plane orientations. Such a detailed,
3D assessment might potentially have an impact on future
recommendations for size selection of the stent-valve that
is - in current clinical practice based - on a single 2D
transoesophageal echocardiographic measurement in the
midoesophageal, long-axis LVOT view. In this context,
Koos et al. [28] have recently demonstrated in a cohort of
TAVI patients that this single echocardiographic measure-
ment correlates well with both CMR and dual-source
computed tomographic measurements of sagittal aortic
annulus diameters, the sagittal long-axis view on CMR
and computed tomography basically having the same
orientation as the midoesophageal long-axis view on echo-
cardiography. In contrast, annulus diameters by transoeso-
phageal echocardiography were significantly smaller than
coronal aortic annulus diameters by CMR and by com-
puted tomography. Regarding the TAVI strategy, the
authors found a perfect agreement between transoesopha-
geal echocardiography and sagittal CMR or computed
tomography measurements. In contrast, decision-making
based on coronal CMR or computed tomography mea-
surements would have modified the TAVI strategy in 22%
and 24% of cases when compared to the echocardiogra-
phy-based strategy.
We could further demonstrate that functional assess-
ment of the implanted stent-valves can be performed
non-invasively using flow-sensitive PC sequences, which
are already used for flow measurements in the clinical
evaluation of valvular heart disease [29,30]. They allow
detection of (para)valvular regurgitation immediately
after valve implantation, which is important in clinical
practice since hemodynamically relevant regurgitation
after TAVI is associated witha ni n c r e a s e di n - h o s p i t a l
mortality [5] and may require immediate post-dilation
of the prosthesis using a balloon or even valve-in-valve
implantation. In our study, no relevant (para)valvular
regurgitation was observed which may not be surprising
in view of the fact that oversized prostheses were used.
Our study clearly shows the advantages of rtCMR-
guided TAVI but also reveals its chief obstacle for trans-
lation into clinical application, namely the lack of suita-
ble, CMR-compatible guidewires providing enough
stiffness. When considering clinical application of
rtCMR-guided TAVI, stiff guidewires are necessary.
However, conventional metallic guidewires and guide-
wires with a nitinol core are not CMR-compatible since
such long conducting structures might couple with the
radiofrequency transmit energy of the body coil; this
coupling could result in amplification of the local elec-
tric field and lead to excessive tissue heating, which pre-
sents a safety hazard precluding clinical application [31].
Currently, CMR-compatible guidewires are polyether-
etherketone-based [20,32] or built from fiberglass [33]
or other non-metallic, reinforced components and are
passively visualized by their susceptibility artifacts, but
do not provide mechanical stability equivalent to the
Figure 8 Post-interventional flow-sensitive PC sequences in parasagittal orientation showing blood flow during diastole (left) and
systole (middle). There is no turbulent flow during systole and also no regurgitant flow during diastole, qualitatively indicating the absence of
relevant valvular and paravalvular regurgitation. Note that - due to the signal shielding effect - the position of the nitinol stent frame is depicted
as a structure filled with image noise. For quantitative assessment, PC flow-curves integrated over time were obtained using through-plane PC
sequences acquired in slices approximately 1 cm below and 1 cm above the prosthesis to avoid the influence of such field distortion effects on
measurements.
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(Amplatz Superstiff, Boston Scientific, MA, USA), as
also shown in our study. Hence, the development of stiff
guidewires suitable for CMR-guided TAVI is warranted.
The development of CMR-compatible, metal-based
guidewires might be an option. The precondition, how-
ever, remains that such guidewires do not act as radio-
frequency antennas and must, consequently, include
measures that counteract radiofrequency heating in the
CMR environment.
When moving towards clinical application of rtCMR
guided TAVI, other procedural and safety aspects
should be taken into consideration and need to be dis-
cussed, specifically an adequate monitoring of heart
rhythm and the issue of rapid right ventricular during
preparatory balloon aortic valvuloplasty as well as an
adequate procedural environment: A detailed ECG-mon-
itoring is an essential prerequisite for TAVI. Arrhyth-
mias (importantly ventricular tachycardia/fibrillation,
bradycardia, atrial fibrillation), conduction abnormalities
(importantly higher-degree AV-blocks, bundle-branch
blocks) and signs of cardiac ischemia (importantly ST-
elevation) need to be accurately assessable. The ECG-
electrodes that have been used in our experimental set-
ting were provided by the CMR scanner’s manufacturer
(Siemens Healthcare Sector, Erlangen, Germany) and
were used for sequence triggering purposes only. With
this setup, a comprehensive ECG-monitoring during a
CMR-guided intervention is not possible. However, we
did not observe any relevant decrease in heart rate/bra-
dycardia suggestive of a higher-degree AV-block after
TAVI. This might potentially be explained by the fact
that implantation was performed into a juvenile, non-
calcified, non-stenosed aortic valve. Nevertheless, a
patient setting would require a CMR-compatible moni-
toring-equipment which is, however, already commer-
cially available (e.g. Schiller MAGLIFE Serenity, Schiller
Ottobrunn, Germany).
At present, balloon aortic valvuloplasty is generally
performed as a preparatory step prior implantation of
current transcatheter aortic valves. In order to prevent
dislodgement of the inflated balloon into the ascending
aorta as a result of cardiac contraction, rapid right-ven-
tricular burst pacing is performed during valvuloplasty
to induce a transient, functional cardiac arrest. Likewise,
rapid right-ventricular pacing is needed for the implan-
tation of the balloon-expandable Edwards prosthesis to
e n s u r eas t a b l ep o s i t i o no ft h es t e n t - v a l v ed u r i n g
implantation. In contrast, the self-expandable CoreValve
prosthesis does not require rapid pacing since its design
allows for nearly continuous trans-aortic blood flow
during stepwise implantation. Moreover, Grube and col-
leagues have recently demonstrated that CoreValve
implantation is also feasible and safe without prior
valvuloplasty [34]. Rapid right-ventricular pacing is,
therefore, not required for CoreValve implantation and
does not present another obstacle for procedural gui-
dance by rtCMR.
Currently, TAVI is ideally performed in so-called
hybrid operating rooms that offer a sterile environment
with full angiographic, anaesthesiological and surgical
equipment. Such rooms not only provide optimal condi-
tions for the procedure but also provide a rapid interdis-
ciplinary team approach for complication management.
While peripheral vascular complications might already
be managed by PTA and stent implantation under
CMR-guidance, other complications might occur that
cannot be addressed within the CMR scanner. Coronary
artery obstruction, for example, may require percuta-
neous coronary intervention or even surgery. Hence, the
CMR scanner should ideally be integrated in the archi-
tectural concept of such a hybrid room, which must
warrant a rapid evacuation of patients from the CMR
scanner in order to perform conventional X-ray guided
intervention or surgery without delay. This can be
ensured either by a swivelling operating table if the
CMR scanner is integrated directly within the hybrid
room or a rail-mounted operating table if the CMR
scanner is accommodated in a separate, adjacent room.
Alternatively, a patient transfer board on a non-mag-
netic patient transporter or even a movable CMR scan-
ner might be considered, although these approaches are
clearly more time-consuming.
As a limitation of our study, it also has to be noted
that patients referred for TAVI usually show somewhat
calcified and tortuous vessels. These vessels may present
a more complex anatomy than seen in our animals.
However, the benefits of the detailed soft-tissue contrast
and 3D representation provided by CMR may be even
more dramatic in these patients. Safe navigation through
the tortuous vascular access routes is presumably sim-
plified by rtCMR to guide operator adjustments and
visualize device-related anatomic distortion. In view of
the stenotic, calcified aortic valve in TAVI patients,
potential CMR imaging artifacts arising from valvular
and aortic root calcifications need to be acknowledged.
Basically, calcifications appear as areas of low signal
intensity or signal void on CMR imaging. Such signal
voids can make edge discrimination of calcified valve
leaflets difficult, especially during direct planimetry of
aortic valve area in a cross-sectional view. They might
also affect rtCMR-guidance of aortic valve passage dur-
ing TAVI. However, in clinical practice, passage of the
stenotic aortic valve is performed with a straight-tip
guidewire in a probing fashion, since neither conven-
tional X-ray angiography nor transoesophageal echocar-
diography allow precise, targeted steering of the wire
through the small orifice. Hence, these imaging artifacts
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they should also not relevantly impair valve positioning
and implantation since the areas of signal void are typi-
cally constraint to the areas of calcification and do not
lead to further image distortion, which might impair
detailed visualization of the relevant anatomical struc-
tures. Thus, the landing zone for the CoreValve prosthe-
sis would still be accurately visible. However, these
considerations remain speculative since a calcific aortic
valve could not be simulated in the pig model. Interest-
ingly, however, successful implantation of an oversized
CoreValve prosthesis in a native, non-stenotic, non-cal-
cified aortic valve without tissue damage and dislocation
might potentially have clinical implications for future
catheter-based treatment of aortic regurgitation which is
currently not an indication for TAVI.
Conclusions
The present in vivo experiments show that TAVI can be
performed solely under rtCMR guidance. Using the com-
mercially available CoreValve bioprosthesis and a modi-
fied, CMR-compatible delivery system which might
potentially be transferred into clinical application without
major additional effort, we could demonstrate that
rtCMR with passive catheter tracking allowed for reliable
monitoring of device navigation, valve positioning, and
implantation across the native aortic annulus. In addition
to immediate detection of procedure-related complica-
tions such as ventricular perforation and pericardial tam-
ponade, CMR - as a single comprehensive imaging
modality - provided a detailed pre-interventional evalua-
tion of the vascular anatomy and of the annulus size as
well as a direct functional assessment after valve implan-
tation. Complimentary to reduction of radiation exposure
and nephrotoxic contrast media, rtCMR guidance, there-
fore, provides advantages over conventional fluoroscopy
and angiography and warrants further attention.
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